Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Impact of the Duration of Diabetes Mellitus on the Outcome of Metastatic Pancreatic Cancer Treated with Gemcitabine: A Retrospective Study.

Iizumi S, Kuchiba A, Okusaka T, Ikeda M, Sakamoto Y, Kondo S, Morizane C, Ueno H, Osame K, Mitsunaga S, Ohno I, Imaoka H, Hashimoto Y, Takahashi H, Sasaki M, Ohashi K.

Intern Med. 2019 Jun 7. doi: 10.2169/internalmedicine.2539-18. [Epub ahead of print]

2.

Chemotherapy and radiotherapy for advanced pancreatic cancer.

Chin V, Nagrial A, Sjoquist K, O'Connor CA, Chantrill L, Biankin AV, Scholten RJ, Yip D.

Cochrane Database Syst Rev. 2018 Mar 20;3:CD011044. doi: 10.1002/14651858.CD011044.pub2. Review.

3.

The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy.

Choi Y, Kim TY, Oh DY, Lee KH, Han SW, Im SA, Kim TY, Bang YJ.

Cancer Res Treat. 2016 Jan;48(1):171-9. doi: 10.4143/crt.2014.292. Epub 2015 Mar 13.

4.

Impact of diabetes mellitus on the survival of pancreatic cancer: a meta-analysis.

Shen H, Zhan M, Wang W, Yang D, Wang J.

Onco Targets Ther. 2016 Mar 22;9:1679-88. doi: 10.2147/OTT.S95744. eCollection 2016.

5.

Impact of diabetes mellitus on epithelial ovarian cancer survival.

Akhavan S, Ghahghaei-Nezamabadi A, Modaresgilani M, Mousavi AS, Sepidarkish M, Tehranian A, Rezayof E.

BMC Cancer. 2018 Dec 12;18(1):1246. doi: 10.1186/s12885-018-5162-3.

6.

ABO blood type, long-standing diabetes, and the risk of pancreatic cancer.

Egawa N, Lin Y, Tabata T, Kuruma S, Hara S, Kubota K, Kamisawa T.

World J Gastroenterol. 2013 Apr 28;19(16):2537-42. doi: 10.3748/wjg.v19.i16.2537.

7.

Combination therapy versus gemcitabine monotherapy in the treatment of elderly pancreatic cancer: a meta-analysis of randomized controlled trials.

Jin J, Teng C, Li T.

Drug Des Devel Ther. 2018 Mar 7;12:475-480. doi: 10.2147/DDDT.S156766. eCollection 2018.

8.

Resolution of new-onset diabetes after radical pancreatic resection predicts long-term survival in patients with pancreatic ductal cell adenocarcinoma.

He XY, Li JF, Yao WY, Yuan YZ.

Ann Surg Oncol. 2013 Nov;20(12):3809-16. doi: 10.1245/s10434-013-3095-2. Epub 2013 Aug 14.

PMID:
23943021
9.

Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone.

Chen H, He R, Shi X, Zhou M, Zhao C, Zhang H, Qin R.

BMC Cancer. 2018 Oct 23;18(1):1034. doi: 10.1186/s12885-018-4948-7.

10.

Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy.

Park I, Choi SJ, Kim YS, Ahn HK, Hong J, Sym SJ, Park J, Cho EK, Lee JH, Shin YJ, Shin DB.

Cancer Res Treat. 2016 Oct;48(4):1264-1273. Epub 2016 Mar 23.

11.

Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer.

Dadi N, Stanley M, Shahda S, O'Neil BH, Sehdev A.

Anticancer Res. 2017 Oct;37(10):5533-5539. Review.

12.

The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients.

Nakai Y, Isayama H, Sasaki T, Takahara N, Saito K, Ishigaki K, Hamada T, Mizuno S, Miyabayashi K, Yamamoto K, Mohri D, Kogure H, Yamamoto N, Ijichi H, Tateishi K, Tada M, Koike K.

J Cancer Res Clin Oncol. 2015 May;141(5):933-9. doi: 10.1007/s00432-014-1873-2. Epub 2014 Nov 15.

PMID:
25398651
13.

Retrospective analysis of efficacy and safety of Gemcitabine-based chemotherapy in patients with metastatic pancreatic adenocarcinoma experiencing disease progression on FOLFIRINOX.

de Jesus VHF, Camandaroba MPG, Donadio MDS, Cabral A, Muniz TP, de Moura Leite L, Sant'Ana LF.

J Gastrointest Oncol. 2018 Oct;9(5):806-819. doi: 10.21037/jgo.2018.06.08.

14.

Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study.

Fernández A, Salgado M, García A, Buxò E, Vera R, Adeva J, Jiménez-Fonseca P, Quintero G, Llorca C, Cañabate M, López LJ, Muñoz A, Ramírez P, González P, López C, Reboredo M, Gallardo E, Sanchez-Cánovas M, Gallego J, Guillén C, Ruiz-Miravet N, Navarro-Pérez V, De la Cámara J, Alés-Díaz I, Pazo-Cid RA, Carmona-Bayonas A.

BMC Cancer. 2018 Nov 29;18(1):1185. doi: 10.1186/s12885-018-5101-3.

15.

Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group.

Irigoyen A, Gallego J, Guillén Ponce C, Vera R, Iranzo V, Ales I, Arévalo S, Pisa A, Martín M, Salud A, Falcó E, Sáenz A, Manzano Mozo JL, Pulido G, Martínez Galán J, Pazo-Cid R, Rivera F, García García T, Serra O, Fernández Parra EM, Hurtado A, Gómez Reina MJ, López Gomez LJ, Martínez Ortega E, Benavides M, Aranda E; Spanish Cooperative Group of Treatment of Digestive Tumors (TTD).

Eur J Cancer. 2017 Apr;75:73-82. doi: 10.1016/j.ejca.2016.12.032. Epub 2017 Mar 7.

PMID:
28222309
16.

Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.

Mukherjee S, Hurt CN, Bridgewater J, Falk S, Cummins S, Wasan H, Crosby T, Jephcott C, Roy R, Radhakrishna G, McDonald A, Ray R, Joseph G, Staffurth J, Abrams RA, Griffiths G, Maughan T.

Lancet Oncol. 2013 Apr;14(4):317-26. doi: 10.1016/S1470-2045(13)70021-4. Epub 2013 Mar 6.

17.
18.

Impact of diabetes mellitus on clinical outcomes of pancreatic cancer after surgical resection: A systematic review and meta-analysis.

Lv X, Qiao W, Leng Y, Wu L, Zhou Y.

PLoS One. 2017 Feb 3;12(2):e0171370. doi: 10.1371/journal.pone.0171370. eCollection 2017. Review.

19.

Impact of diabetes mellitus on clinical outcomes in patients undergoing surgical resection for pancreatic cancer: a retrospective, cohort study.

Hart PA, Law RJ, Frank RD, Bamlet WR, Burch PA, Petersen GM, Rabe KG, Chari ST.

Am J Gastroenterol. 2014 Sep;109(9):1484-92. doi: 10.1038/ajg.2014.193. Epub 2014 Jul 29.

20.

Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer.

Wu Z, Gabrielson A, Hwang JJ, Pishvaian MJ, Weiner LM, Zhuang T, Ley L, Marshall JL, He AR.

Cancer Chemother Pharmacol. 2015 Dec;76(6):1309-14. doi: 10.1007/s00280-015-2855-z. Epub 2015 Oct 27.

PMID:
26507197

Supplemental Content

Support Center